Simcere Pharmaceutical Group Ltd. announced that its subsidiary, Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., has entered into an exclusive licensing agreement with Ipsen Pharma SAS. Under the terms of the agreement, Ipsen will have exclusive global rights, outside of Greater China, for the development, manufacturing, and commercialization of SIM0613, a LRRC15-targeting antibody-drug conjugate developed by Jiangsu Zaiming. The agreement includes a US$45 million upfront payment to Simcere, with the potential for up to US$1,060 million in total payments, including development, regulatory, and commercial milestones, as well as tiered royalties on sales, contingent on successful development and regulatory approvals.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251222-11963004), on December 22, 2025, and is solely responsible for the information contained therein.